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Over-expression and single-step purification of human IFNα8 and 
human IFNα2b reveals the highest antiviral activity of human IFNα8
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Background
Human alpha interferons (HuIFNα) comprise a multigene
family, originally identified as proteins responsible for the
induction of cellular resistance to viral infections, subdi-
vided into 13 different subtypes (IFNα1, α2, α4, α5, α6, α7, α8,
α10, α13, α14, α16, α17 and α21). The genes that encode these
proteins are clustered on chromosome 9 in human [1].
There have been reports of obvious differences in the rel-
ative biologicals activities among IFNα subtypes [2,3] and
it was found that the activity varied greatly depending on
the target cells, the IFNα subtypes and even if the proteins
were compared on base of both units of biological activity
or mass [4]. The HuIFNα2b and HuIFNα8 are among the IFN
subtypes with highest antiviral activity. The first one was
licensed by the Food and Drug Administration in 1986
(USA) for the treatment of hairy cell leukemia [5]. On the
other hand, the HuIFNα8 has shown the highest biological
activity in several in vitro assays [6-8].
Several progresses in the fundamental understanding of
transcription, translation, and protein folding in
Escherichia coli, together with the availability of improved
genetic tools (including new mutants) are making this
bacterium more valuable than ever for the expression of
complex eukaryotic proteins. Several strategies have been
required to enhance rare codons gene expression [9,10].
Homogenous HuIFNα preparations were originally
obtained in 1978 for further chemical and physical char-
acterization [11]. Thereafter have been introduced new
high performance chromatography techniques useful to
obtain enough quantity of these proteins for their chemi-
cal, biological and immunological studies [12]. Although
high quantities of these proteins could be obtained, these
procedures involve costly and laborious purification pro-
tocols.
In our previous report we attempted to over express the
HuIFNα8 in E. coli without success [13]. In the present
work, the heterologous expression of both HuIFNα8 and
HuIFNα2b was significantly improved. These proteins were
purified by one step and low cost SDS-PAGE procedure
and used for detailed chemical and physic characteriza-
tion. Both HuIFNα subtypes obtained were used to com-
pare its antiviral activity by using an in vitro model
involving Hep-2 cells challenged with Mengo virus [14].
Results
Comparing the rare codon compositions of both HuIFNα
subtypes, two clusters of 30 amino acids, containing five
minor triplets, were found (see Figure 1). For the HuIFNα2b
gene, the minor codons, represented only by AGG/AGA
(that encodes for Arg) are present in both clusters. How-
ever, besides the minor triplets that encodes for Arg, in the
HuIFNα8 gene one minor codon AUA (ATA triplet, that
encodes for Ile) is present in the first cluster, while in the
second one, the CUA (CTA triplet, that encodes for Leu)
exists.
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both HuIFNα genes, E. coli BL21-codonplus-RIL cells (Strat-
agene, USA) were used to increase the heterologous
polypeptides expression levels. E. coli BL21-codonplus-
RIL cells were transformed with the plasmids pALF8-4 and
pAGUA-4 [13] coding for HuIFNα8 and HuIFNα2b, respec-
tively. This strain carries out additional copies of the dnaY,
ileY and leuW tRNAs in an additional Cmr pACYC deriva-
tive plasmid. The last two tRNA decode the AUA and CUA
minor codons, respectively. The obtained transformants
were grown in M9 minimum medium. For HuIFNα8 trans-
formants, the protein expression level increased from 1%
(with E. coli BL-21/pALF8-4) up to 25% (with E. coli BL-
21 CP RIL/pALF8-4) of total bacterial proteins based on
densitometric analysis of scanned gels (see Figure 2). Sim-
ilar results were obtained with the HuIFNα2b Ampr-Cmr
transformants, the expression levels increased from 5%
(with E. coli BL-21/pAGUA-4) up to around 20% (with E.
coli BL-21CPRIL/pAGUA-4) of total host proteins.
The purity of purified HuIFNα subtypes was estimated over
98%, based on the homogeneity observed in the silver
Expression of both HuIFNα subtypes in E. coli cells grown in minimum mediaFigure 2
Expression of both HuIFNα subtypes in E. coli cells grown in minimum media. (A) 12.5% SDS-PAGE stained with Coomassie 
blue, and (B) Immunoblotting analysis using a mixture of rabbit polyclonal antibodies specific for both HUIFNα2 and HUIFNα8. 
Samples: (1) E. coli BL-21/ pALF8-4, (2) E. coli BL-21CP RIL/ pALF8-4, (3), E. coli BL-21CP RIL/ pAGUA-4, (4) E. coli BL-21/ 
pAGUA-4, (5) E. coli BL-21CP RIL. The molecular weight markers (M) are indicated (M).
(A)                                               (B) 






Clusters of 30 aminoacid presents in bothHuIFNα subtypesFigure 1
Clusters of 30 aminoacid presents in bothHuIFNα subtypes. In boxes, the AGA/AGG triplets coding for Arginine. The ATA and 
CTA triplets coding for Isoleucine and Leucine, respectively, are underlined.Page 2 of 4
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3).
The antiviral potency of both HuIFNα subtypes was com-
pared in an in vitro assay with one microgram of each pro-
tein challenged with mengo virus [14]. Results of five
independent experiments are shown in the table 1. The
HuIFNα8 had 1,46 fold more antiviral activity than
HuIFNα2b (p < 0,05) in this biological system.
(A). RP-HPLC analysis of purified HUIFNα2 (A) and HUIFNα8 (B)Figure 3
(A). RP-HPLC analysis of purified HUIFNα2 (A) and HUIFNα8 (B). The molecular weight of markers shown in SDS-PAGE are: 34 
kDa, 26 kDa, 20 kDa and 7 kDa, respectively. (B). The LC-MS analysis of the tandem digestion tryptic/V8 revealed that cysteine 
residues of HuIFNα8 and HuIFNα2b are correctly linked by disulfide bridges ((Data not show).
(A)
(B)
Table 1: Antiviral potency of both purified HuIFNα subtypes.
Sample Titer 1 Titer 2 Titer 3 Titer 4 Titer 5 Titer average
HuIFNa8 5.1 4.5 4.8 3.9 4.1 4.48 (3.86-5.09)a
HuIFNa2b 2.3 2.8 2.5 3 2.1 2.54 (2.08-2.99)a
E. coli BL-21 CP RIL nd nd nd nd nd nd
The titer values are expressed in 106 international units. nd, not antiviral activity detectable.
a Values in parenthesis correspond to confidence limits (p < 0.05).Page 3 of 4
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In summary, this work highlights several issues to obtain
human proteins with high molecular homogeneity avoid-
ing costly and tedious purification procedures. Therefore,
we recommend this experimental strategy to obtain
humans proteins with high therapeutic potentials. The
highest antiviral activity of HuIFNα8 shown in vitro add
new evidences to take into account this proteins as strong
therapeutic candidate.
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